(Q48530603)

12 February 2018

title

Chemokine receptor - Directed imaging and therapy (English)

1 reference

12 February 2018

author name string

Andreas K Buck

1

1 reference

12 February 2018

Antje Stolzenburg

2

1 reference

12 February 2018

Heribert Hänscheid

3

1 reference

12 February 2018

Andreas Schirbel

4

1 reference

12 February 2018

Katharina Lückerath

5

1 reference

12 February 2018

Margret Schottelius

6

1 reference

12 February 2018

Hans-Jürgen Wester

7

1 reference

12 February 2018

Constantin Lapa

8

1 reference

12 February 2018

publication date

12 September 2017

1 reference

12 February 2018

published in

Methods

1 reference

12 February 2018

volume

130

1 reference

12 February 2018

page(s)

63-71

1 reference

12 February 2018

A review on CXCR4/CXCL12 axis in oncology: no place to hide.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Involvement of chemokine receptors in breast cancer metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Molecular imaging of chemokine receptor CXCR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

[177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Preclinical evaluation of a CXCR4-specific (68)Ga-labelled TN14003 derivative for cancer PET imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

CXCR4-targeted near-infrared imaging allows detection of orthotopic and metastatic human osteosarcoma in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

[(68)Ga]Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Intraindividual tumor heterogeneity in NET - Further insight by C-X-C motif chemokine receptor 4-directed imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Integrating MRI and chemokine receptor CXCR4-targeted PET for detection of leukocyte infiltration in complicated urinary tract infections after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

[68Ga]Pentixafor-Positron Emission Tomography/Computed Tomography Detects Chemokine Receptor CXCR4 Expression After Ischemic Stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer 68Ga-Pentixafor for PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque using (68)Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.09.002

10.1016/J.YMETH.2017.09.002

7 January 2021

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018